BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

29 articles for X Xing

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.EBI
Massachusetts Institute of Technology
Synthesis and evaluation of 2-[2-(phenylthiomethyl)-1H-benzo[d] imidazol-1-yl)acetohydrazide derivatives as antitumor agents.EBI
Sichuan University
Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.EBI
Harvard Medical School
Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies.EBI
Shandong First Medical University & Shandong Academy of Medical Sciences
Optimization of a series of heterocycles as survival motor neuron gene transcription enhancers.EBI
Harvard Medical School
Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy.EBI
Indiana University School of Medicine
Compounds for degrading alpha-synuclein aggregates and uses thereofBDB
Aprinoia Therapeutics
TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDSBDB
Csic
Pyrazolopyrimidine compounds as adenosine receptor antagonistsBDB
Exscientia
Isoquinolin-3-yl carboxamides and preparation and use thereofBDB
Biosplice Therapeutics
Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereofBDB
Suzhou Longbiotech Pharmaceuticals
Quaternary lactam compound and pharmaceutical use thereofBDB
Shanghai Meiyue Biotech Development
hTRPV1 chemical agentsBDB
University of Pittsburgh
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseBDB
Shy Therapeutics
Compound for inhibiting IDO, a manufacturing method and a use thereofBDB
Shanghai Joyu Pharmatech
Benzimidazole derivatives as PI3 kinase inhibitorsBDB
Glaxosmithkline
Amino pyrimidine derivativesBDB
Novartis
Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregationBDB
Bristol-Myers Squibb
P2X7 modulatorsBDB
Janssen Pharmaceutica
New protein farnesyltransferase inhibitors in the 3-arylthiophene 2-carboxylic acid series: diversification of the aryl moiety by solid-phase synthesis.BDB
Centre De Recherche De Gif
Kinase inhibitorsBDB
Allergan
Aminopyridine derived compounds as LRRK2 inhibitorsBDB
H. Lundbeck
Difluorolactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditionsBDB
Cayman Chemical
N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides and their use as pharmaceuticalsBDB
Sanofi
Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereofBDB
Bristol-Myers Squibb
Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor.BDB
Karo Bio